| Primary |
| Prostate Cancer Metastatic |
27.5% |
| Prostate Cancer |
18.9% |
| Premedication |
14.3% |
| Hormone-refractory Prostate Cancer |
11.7% |
| Hypertension |
4.9% |
| Product Used For Unknown Indication |
3.8% |
| Prophylaxis |
3.4% |
| Diabetes Mellitus |
3.0% |
| Atrial Fibrillation |
1.5% |
| Bone Pain |
1.5% |
| Hypercholesterolaemia |
1.5% |
| Chemotherapy |
1.1% |
| Constipation |
1.1% |
| Gastrooesophageal Reflux Disease |
1.1% |
| Anxiety |
0.8% |
| Blood Glucose |
0.8% |
| Blood Pressure |
0.8% |
| Metastases To Bone |
0.8% |
| Nausea |
0.8% |
| Osteopenia |
0.8% |
|
| Thrombocytopenia |
16.9% |
| Death |
10.2% |
| Sepsis |
10.2% |
| Septic Shock |
6.8% |
| Vomiting |
6.8% |
| Haematuria |
5.1% |
| Paraesthesia |
5.1% |
| Pyrexia |
5.1% |
| Syncope |
5.1% |
| Enteritis |
3.4% |
| Leukocytosis |
3.4% |
| Nausea |
3.4% |
| Neutropenia |
3.4% |
| Paraplegia |
3.4% |
| Pulmonary Embolism |
3.4% |
| Anaphylactic Shock |
1.7% |
| Angiopathy |
1.7% |
| Bone Marrow Failure |
1.7% |
| Cardiac Failure |
1.7% |
| Central Nervous System Lesion |
1.7% |
|
| Secondary |
| Prostate Cancer Metastatic |
43.8% |
| Hormone-refractory Prostate Cancer |
10.8% |
| Premedication |
8.8% |
| Prostate Cancer |
7.8% |
| Prophylaxis |
5.2% |
| Hypertension |
4.6% |
| Bone Pain |
3.9% |
| Diabetes Mellitus |
2.9% |
| Anxiety |
2.0% |
| Constipation |
1.3% |
| Metastases To Bone |
1.3% |
| Product Used For Unknown Indication |
1.3% |
| Atrial Fibrillation |
1.0% |
| Bronchospasm |
1.0% |
| Neuralgia |
1.0% |
| Pulmonary Embolism |
1.0% |
| Vertigo |
1.0% |
| Type Ii Diabetes Mellitus |
0.7% |
| Coronary Artery Disease |
0.3% |
| Hyperlipidaemia |
0.3% |
|
| Septic Shock |
16.7% |
| Pollakiuria |
12.5% |
| Thrombocytopenia |
12.5% |
| Death |
8.3% |
| Paraplegia |
6.3% |
| Sudden Death |
6.3% |
| Haematuria |
4.2% |
| Overdose |
4.2% |
| Prostate Cancer Metastatic |
4.2% |
| Syncope |
4.2% |
| Enteritis |
2.1% |
| Fatigue |
2.1% |
| Hypokalaemia |
2.1% |
| Hypotonia |
2.1% |
| Leukocytosis |
2.1% |
| Leukopenia |
2.1% |
| Nausea |
2.1% |
| Neoplasm Progression |
2.1% |
| Neuropathy Peripheral |
2.1% |
| Neutropenia |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
31.6% |
| Prostate Cancer Metastatic |
23.7% |
| Prostate Cancer |
15.8% |
| Premedication |
7.9% |
| Hypertension |
5.3% |
| Prophylaxis |
5.3% |
| Blood Cholesterol Increased |
2.6% |
| Bone Cancer |
2.6% |
| Metastases To Bone |
2.6% |
| Pain |
2.6% |
|
| Prostate Cancer |
16.7% |
| Febrile Neutropenia |
8.3% |
| Hypocalcaemia |
8.3% |
| Incorrect Route Of Drug Administration |
8.3% |
| Memory Impairment |
8.3% |
| Osteonecrosis Of Jaw |
8.3% |
| Tooth Extraction |
8.3% |
| Toothache |
8.3% |
| Transient Ischaemic Attack |
8.3% |
| Vitamin D Decreased |
8.3% |
| Weight Decreased |
8.3% |
|
